Toll Free: 1-888-928-9744
Published: Jul, 2015 | Pages:
37 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Vectura Group Plc - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Vectura Group plc - Product Pipeline Review - 2015', provides an overview of the Vectura Group plc's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Vectura Group plc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Vectura Group plc including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Vectura Group plc's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Vectura Group plc's pipeline products Reasons to buy - Evaluate Vectura Group plc's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Vectura Group plc in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Vectura Group plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Vectura Group plc and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Vectura Group plc - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Explore the dormant and discontinued projects of Vectura Group plc and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Vectura Group Plc Snapshot 5 Vectura Group Plc Overview 5 Key Information 5 Key Facts 5 Vectura Group Plc - Research and Development Overview 6 Key Therapeutic Areas 6 Vectura Group Plc - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Partnered Products 10 Partnered Products/Combination Treatment Modalities 11 Pipeline Products - Out-Licensed Products 12 Out-Licensed Products/Combination Treatment Modalities 13 Vectura Group Plc - Pipeline Products Glance 14 Vectura Group Plc - Late Stage Pipeline Products 14 Phase III Products/Combination Treatment Modalities 14 Vectura Group Plc - Clinical Stage Pipeline Products 15 Phase II Products/Combination Treatment Modalities 15 Phase I Products/Combination Treatment Modalities 16 Vectura Group Plc - Early Stage Pipeline Products 17 Preclinical Products/Combination Treatment Modalities 17 Vectura Group Plc - Drug Profiles 18 VR-475 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 VR-876 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 VR-096 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 VR-647 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 VR-736 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Drug for Pulmonary Hypertension 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 VR-588 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Vectura Group Plc - Pipeline Analysis 25 Vectura Group Plc - Pipeline Products by Target 25 Vectura Group Plc - Pipeline Products by Route of Administration 26 Vectura Group Plc - Pipeline Products by Molecule Type 27 Vectura Group Plc - Pipeline Products by Mechanism of Action 28 Vectura Group Plc - Recent Pipeline Updates 29 Vectura Group Plc - Dormant Projects 31 Vectura Group Plc - Discontinued Pipeline Products 32 Discontinued Pipeline Product Profiles 32 VR-611 32 Vectura Group Plc - Company Statement 33 Vectura Group Plc - Locations And Subsidiaries 35 Head Office 35 Other Locations & Subsidiaries 35 Appendix 36 Methodology 36 Coverage 36 Secondary Research 36 Primary Research 36 Expert Panel Validation 36 Contact Us 36 Disclaimer 37
List of Tables
Vectura Group Plc, Key Information 5 Vectura Group Plc, Key Facts 5 Vectura Group Plc - Pipeline by Indication, 2015 7 Vectura Group Plc - Pipeline by Stage of Development, 2015 8 Vectura Group Plc - Monotherapy Products in Pipeline, 2015 9 Vectura Group Plc - Partnered Products in Pipeline, 2015 10 Vectura Group Plc - Partnered Products/ Combination Treatment Modalities, 2015 11 Vectura Group Plc - Out-Licensed Products in Pipeline, 2015 12 Vectura Group Plc - Out-Licensed Products/ Combination Treatment Modalities, 2015 13 Vectura Group Plc - Phase III, 2015 14 Vectura Group Plc - Phase II, 2015 15 Vectura Group Plc - Phase I, 2015 16 Vectura Group Plc - Preclinical, 2015 17 Vectura Group Plc - Pipeline by Target, 2015 25 Vectura Group Plc - Pipeline by Route of Administration, 2015 26 Vectura Group Plc - Pipeline by Molecule Type, 2015 27 Vectura Group Plc - Pipeline Products by Mechanism of Action, 2015 28 Vectura Group Plc - Recent Pipeline Updates, 2015 29 Vectura Group Plc - Dormant Developmental Projects,2015 31 Vectura Group Plc - Discontinued Pipeline Products, 2015 32 Vectura Group Plc, Subsidiaries 35
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.